Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.
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Abstract 1 Multicentric Castleman's disease (MCD) is an uncommon lymphoproliferative disorder, often 2 associated with a clinically aggressive behavior. No standard treatment has been 3 established, but patients are usually treated with lymphoma-type regimens such as 4 rituximab or combination chemotherapy. Recently, immunotherapies targeting IL-6 have 5 proven effective and have been approved for this indication. However, these agents require 6 long-term administration. Here, we describe the clinical course of two patients, refractory to 7 rituximab and chemotherapy, showing long-term remission (18 and 24 months), following an 8 induction phase with tocilizumab (an anti-IL-6 receptor antibody) and a consolidative phase 9 with high-dose melphalan accompanied by autologous stem cell support. This may prove to 10 be an effective option for this group of patients with an orphan disorder. Here, we describe long-term control in two patients with multiple relapsed iMCD using anti-1 IL6 receptor immunotherapy (tocilizumab), consolidated with high dose melphalan. 
